Inhibition of B-Catenin and Bcr-Abl Tyrosine Kinase Synergistically Targets Blast Crisis CML Cells and Stem/Progenitor Cells In Vitro and In Vivo

Bcr-Abl tyrosine kinase inhibitors (TKIs) have revolutionized CML treatment. However, these agents have limited activity against blast crisis (BC) CML, and are unable to eliminate leukemia stem cells. Interestingly, β-catenin, required for the maintenance of CML stem cells is constitutively activated in BC CML, which reputedly drives BC self-renewal capacity.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Source Type: research